MitraClip combined with PTSBME for the treatment of obstructive hypertrophic cardiomyopathy with severe mitral regurgitation: a case report

MitraClip联合PTSBME治疗伴有重度二尖瓣反流的梗阻性肥厚型心肌病:病例报告

阅读:2

Abstract

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the hereditary cardiomyopathy with the highest incidence rate. Its main pathological changes are ventricular septal myocardial hypertrophy and myocardial disorder, which are prone to fatal arrhythmia and heart failure. If left ventricular outflow tract (LVOT) obstruction is combined, it is called obstructive hypertrophic cardiomyopathy (oHCM). There is currently no report on the use of MitraClip combined with percutaneous transluminal septal branch microsphere embolization (PTSBME) for treating patients with oHCM complicated with severe mitral regurgitation (MR). CASE PRESENTATION: This report describes a 51-year-old male patient who was admitted to the hospital due to "repeated chest tightness and shortness of breath for 2 years, worsening for 6 months". Ultrasound, left ventricular angiography (LVA), and left cardiac catheterization confirmed oHCM with moderate MR. We used MitraClip combined with PTSBME to relieve the patient's LVOT obstruction and MR simultaneously. CONCLUSIONS: Traditionally, both interventricular septal and mitral valve lesions are treated simultaneously through surgical intervention. However, the surgical conditions are relatively strict, and many patients are unable to undergo surgical treatment, resulting in delays in their condition. For such patients, minimally invasive intervention may be used to simultaneously treat interventricular septal and mitral valve lesions, further reducing surgical risks and enhancing surgical efficacy. In this case, MitraClip combined with PTSBME was first performed. After the surgery, the patient's LVOT obstruction and MR were simultaneously relieved, and clinical symptoms improved significantly.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。